Related Experiment Video
Updated: Jun 3, 2025
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
Potential biomarkers for MCL1 inhibitor sensitivity
1Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, IL 60612, USA.
Abstract:
MCL1 is an anti-apoptotic member of the BCL2 protein family, and its overexpression is associated with poor prognosis across various cancers. Small molecule inhibitors targeting MCL1 are currently in clinical trials for TNBC and other malignancies. However, one major challenge in the clinical application of MCL1 inhibitors is the inherent or acquired resistance to these drugs. Additionally, there is a lack of predictive biomarkers to identify which tumors will respond to MCL1 inhibition. We identified a four-gene functional signature that promotes MCL1 inhibitor resistance in TNBC cells. This gene signature (GS) can distinguish resistant from sensitive TNBC cell lines. Factors encoded by these four genes promote MCL1 inhibitor resistance at least in part through regulation of the ERK signaling pathway. This mechanism involves the upregulation of BCL2 and the downregulation of BIM, which contribute to the inhibitor resistance. Thus, we have discovered a functional GS that drives MCL1 inhibitor resistance. Currently, the MCL1 inhibitor GS-9716 is in clinical trials for TNBC therapy. If validated in clinical samples, this GS could potentially serve as a predictive biomarker for therapy response and help guide the selection of combination therapies to enhance the effectiveness of MCL1 inhibitors.
Insights
Researchers identified a four-gene signature that predicts resistance to MCL1 inhibitors in triple-negative breast cancer (TNBC). This signature may guide treatment selection for patients receiving MCL1 inhibitor therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- MCL1, an anti-apoptotic protein, is overexpressed in many cancers, correlating with poor prognosis.
- MCL1 inhibitors show promise for treating triple-negative breast cancer (TNBC) and other malignancies.
- Drug resistance and lack of predictive biomarkers limit the clinical efficacy of MCL1 inhibitors.
Purpose of the Study:
- To identify a functional gene signature (GS) that predicts resistance to MCL1 inhibitors in TNBC.
- To elucidate the molecular mechanisms underlying MCL1 inhibitor resistance.
- To explore the potential of the identified GS as a predictive biomarker for TNBC therapy.
Main Methods:
- Analysis of gene expression in TNBC cell lines with varying sensitivity to MCL1 inhibitors.
- Functional validation of a four-gene signature associated with resistance.
- Investigation of the role of the ERK signaling pathway in mediating resistance.
Main Results:
- A four-gene signature was identified that distinguishes MCL1 inhibitor-resistant from sensitive TNBC cell lines.
- The identified genes promote resistance, partly through regulating the ERK signaling pathway.
- This mechanism involves altered expression of BCL2 and BIM, contributing to drug resistance.
Conclusions:
- A functional gene signature driving MCL1 inhibitor resistance in TNBC has been discovered.
- This signature may serve as a predictive biomarker for patient response to MCL1 inhibitors.
- The findings could inform combination therapy strategies to overcome resistance and improve treatment outcomes.
